Search

Your search keyword '"Mitsuyama, Hideo"' showing total 30 results
Start Over Author "Mitsuyama, Hideo"
30 results on '"Mitsuyama, Hideo"'

17. Two Cases of Acute Exacerbation of Interstitial Pneumonia Treated with Polymyxin B-immobilized Fiber Column Hemoperfusion Treatment

Author

Noma, Satoshi, primary, Matsuyama, Wataru, additional, Mitsuyama, Hideo, additional, Suetsugu, Takayuki, additional, Koreeda, Yoshimizu, additional, Mizuno, Keiko, additional, Higashimoto, Ikkou, additional, Kakihana, Yasuyuki, additional, Hashiguchi, Teruto, additional, Maruyama, Ikuro, additional, Osame, Mitsuhiro, additional, and Arimura, Kimiyoshi, additional

Published
2007
Full Text
View/download PDF

24. Improving visual acuity with nivolumab plus ipilimumab plus two cycles of chemotherapy following a diagnosis of lung adenocarcinoma with choroidal metastasis: A case report and literature review.

Author

Matsuyama T, Oniwa M, Tsuruzono K, Yasuda S, Yone M, Tomioka Y, Uchida A, Mitsuyama H, Kubota S, Suetsugu T, Mizuno K, and Inoue H

Abstract

A 75-year-old woman presented at our hospital with bilateral visual impairment. Ophthalmological examination revealed multiple choroidal tumours. Chest computed tomography revealed a tumour shadow in the right lower lobe and multiple lymph node metastases in the mediastinum and pulmonary hilum. Following a detailed examination, the patient was diagnosed with primary lung adenocarcinoma (cT1cN3M1c Stage IVB) with choroid metastases. The tumour proportion score of programmed death ligand 1 (PD-L1) was 1% and EGFR exon 20 insertion mutations were also detected. The patient was administered combination chemotherapy with nivolumab and ipilimumab. Primary lung and metastatic tumours, including the choroid, were reduced, and visual disturbances improved completely. Herein, we describe a rare case in which a combination of chemotherapy with nivolumab and ipilimumab significantly reduced vision loss due to choroidal metastasis., Competing Interests: Hiromasa Inoue reports grants from Boehringer‐Ingelheim and Kyorin, and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events to AstraZeneca, Boehringer‐Ingelheim, Kyorin, GlaxoSmithKline and Novartis and Sanofi., (© 2023 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology.)

Published
2023
Full Text
View/download PDF

29. [Bronchial asthma attack with lactic acidosis and hypokalemia in a case receiving high dose inhalation of procaterol hydrochloride].

Author

Noma S, Kubota S, Matsukizono K, Tanoue A, Kumamoto T, Taira T, Mitsuyama H, Kawabata T, Suetsugu T, Iwakaw J, Koreed Y, Matsuyama W, Mizuno K, Higashimoto I, Osame M, and Arimura K

Subjects
Administration, Inhalation, Adrenergic beta-Agonists administration & dosage, Adult, Humans, Male, Procaterol administration & dosage, Acidosis, Lactic chemically induced, Adrenergic beta-Agonists adverse effects, Asthma drug therapy, Hypokalemia chemically induced, Procaterol adverse effects
Abstract

We report a case of bronchial asthma attack with lactic acidosis and hypokalemia in a patient receiving high-dose inhalation of procaterol hydrochloride. A 28-year-old man was transferred to our hospital because of adynamia, nausea and dyspnea. He had used inhaled procaterol hydrochloride with a pressurized metered dose inhaler about 20 times before admission. On admission, there were no signs of shock state or hypoxemia and laboratory data showed hypokalemia, hyperglycemia and metabolic acidosis with elevated anion gap. Lactic acidosis was identified as the reason for the metabolic acidosis with elevated anion gap. Lactic acidosis improved after 12 hours. Lactic acidosis due to high dose inhalation of procaterol hydrochloride was suggested.

Published
2007

30. [Two lung adenocarcinoma patients with multiple brain metastasis treated with Gefitinib and surviving more than 2 years].

Author

Matsuyama W, Yamamoto M, Machida K, Mitsuyama H, Watanabe M, Higashimoto I, Osame M, and Arimura K

Subjects
Adenocarcinoma, Papillary secondary, Aged, Aged, 80 and over, Bone Neoplasms radiotherapy, Bone Neoplasms secondary, Brain Neoplasms drug therapy, Drug Administration Schedule, Female, Gefitinib, Humans, Lung Neoplasms pathology, Radiotherapy Dosage, Survivors, Adenocarcinoma, Papillary drug therapy, Antineoplastic Agents therapeutic use, Brain Neoplasms secondary, Lung Neoplasms drug therapy, Quinazolines therapeutic use
Abstract

Case 1 is a 78-year-old woman in whom lung adenocarcinoma with multiple brain metastasis (cT2N3M1, stage IV) was diagnosed. She was treated with Gefitinib alone. Her lung tumor and metastatic brain lesions decreased 6 months after the start of therapy. She has no recurrence and is still alive with a good performance status after 25 months. Case 2 is an 80-year-old woman in whom lung adenocarcinoma with multiple brain (cT2N3M1, stage IV) was diagnosed. She was also treated with Gefitinib alone and her lung tumor and metastatic brain becomes improved 6 months after the start of therapy. She maintained a good performance status for more than 2 years (29 months). However, 29 months after beginning treatment, she had recurrence in bone and died 2 months later, 31 months after the start of therapy. The prognosis of non-small cell lung cancer with multiple brain metastasis is very poor and the efficacy of chemotherapy for the treatment of multiple brain metastases is limited, and longterm survival remains disappointing. We report two lung adenocarcinoma patients with multiple brain metastasis who survived more than 2 years by treatment with Gefitinib alone.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results